BOSTON--(BUSINESS WIRE)--Cerveau Technologies Inc. today announced a research collaboration with University College London (UCL), a leading UK academic center for the production and application of imaging biomarkers for use in clinical research, that grants the institution the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent. The facility has been fully qualified by Cerveau to produce the tracer. This will facilitate clinical studies at UCL and associated centers of excellence for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease
UCL joins a group of GMP producers in the United States, Singapore, Australia, Japan, and the EU for this tau ligand, and is the first able to distribute GMP-produced [18F]MK-6240 in the United Kingdom.
Professor Erik Arstad, the Director of the UCL Centre for Radiopharmaceutical Chemistry, said “The team at the UCL Centre for Radiopharmaceutical Chemistry is delighted to provide [18F]MK-6240 to our clinical collaborators at the UCL Dementia Research Centre and the wider biomedical research community in the UK. As the best-in-class imaging biomarker for neurofibrillary tangles (NFTs) in the brain, [18F]MK-6240 will facilitate UK led research into the understanding and treatment of Alzheimer’s Disease.”
“We are enthusiastic about working with the team at UCL and making the tracer broadly accessible for investigations in the UK. We believe that the expertise and collaboration we have seen from the UCL team is a great indication of a promising collaboration between Cerveau and UCL to enable broad access for scientific research and clinical trial support.” said Rick Hiatt, President and CEO of Cerveau Technologies, Inc. “Cerveau has been able to build a robust production network for MK-6240 in the United States and is now looking to expand Global and European access of this tracer for clinical investigations.”
About Cerveau Technologies, Inc.
Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.
About University College London.
As London's leading multidisciplinary university, UCL is working with a diverse group of international partners to tackle the great global challenges of our time.
